Skip to main content

Olivier Kassel

Olivier Kassel (PI; Karlsruhe Institute of Technology, KIT)

Project(s) involved: Kassel/Di Ventura

 

Curriculum Vitae Olivier Kassel

Date of birth:           31.03.1968

Nationality               French

Marital status:         Married, one child

 

Address:                 Karlsruhe Institute of Technology

Institute of Toxicology and Genetics

Hermann-von-Helmholtz-Platz 1

76344 Eggenstein-Leopoldshafen

Tel.: 0721 608 23911

 

Employment

2008-present          Group Leader, Institute of Toxicology and Genetics, Karlsruhe Institute of Technology (KIT), Karlsruhe

2004-2008              Project Leader, Institut für Toxikologie und Genetik, Forschungszentrum Karlsruhe

1999-2004              Post-doctorant, Institut für Toxikologie und Genetik, Forschungszentrum Karlsruhe

1995-1998              “Allocataire de Recherche du Ministère de l’Education Nationale, de la Recherche et de la Technologie”, INSERM, U425, Strasbourg (France)

1993                       Research Assistant. Department of Clinical Pharmacology, University of Southampton (UK)

 

Education

1995-1999              PhD in Molecular and Cellular Pharmacology (Université Louis Pasteur, Strasbourg I)

1994-1995              Postgraduate Degree in Pharmacology and Pharmacochemistry, specialisation in Molecular and Cellular Pharmacology (Diplôme d'Études Approfondies, Université Louis Pasteur, Strasbourg I)

1988-1991              Master of Biological and Medical Sciences (Université Louis Pasteur, Strasbourg I).

1986-1992              Pharm. D. (School of Pharmacy, Université Louis Pasteur, Strasbourg I, France).

 

Scholarships, Fellowships and awards

1994-1995              Postgraduate training scholarship, Université Louis Pasteur, Strasbourg I

1995-1998              Doctoral fellowship, Ministère de l’Education Nationale, de la Recherche et de la Technologie

1999-2000              Post-doctoral fellowship. Institut National de la Santé et de la Recherche Médicale - Deutsche Forschungsgemeinshaft (INSERM-DFG) exchange programme

2002                       Schoeller-Junkmann-Preiss 2002 awarded by the German Endocrine Society for work in the field of glucocorticoid receptor action

2004                       Enrolled in the High Potential Program of the Forschungszentrum Karlsruhe (tenure position)

 

Selected publications

Chakraborty A, Diefenbacher ME, Mylona A, Kassel O & Behrens A (2015) The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling. Nat Commun 6: 6782

Diefenbacher ME, Reich D, Dahley O, Kemler D, Litfin M, Herrlich P & Kassel O (2014) The LIM Domain Protein nTRIP6 Recruits the Mediator Complex to AP-1-Regulated Promoters. PLoS ONE 9: e97549

Röder IV, Strack S, Reischl M, Dahley O, Khan MM, Kassel O, Zaccolo M & Rudolf R (2012) Participation of Myosin va and pka type I in the regeneration of neuromuscular junctions. PLoS ONE 7: e40860

Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M & Sleeman JP (2012) CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci 69: 435–448

Diefenbacher ME, Litfin M, Herrlich P & Kassel O (2010) The nuclear isoform of the LIM domain protein Trip6 integrates activating and repressing signals at the promoter-bound glucocorticoid receptor. Mol Cell Endocrinol 320: 58–66

Diefenbacher M, Sekula S, Heilbock C, Maier JV, Litfin M, van Dam H, Castellazzi M, Herrlich P & Kassel O (2008) Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol Endocrinol 22: 1767–1780

Kassel O & Herrlich P (2007) Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol Cell Endocrinol 275: 13–29

Kassel O, Schneider S, Heilbock C, Litfin M, Göttlicher M & Herrlich P (2004) A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev 18: 2518–2528

Da Silva CA, Heilbock C, Kassel O & Frossard N (2003) Transcription of stem cell factor (SCF) is potentiated by glucocorticoids and interleukin-1beta through concerted regulation of a GRE-like and an NF-kappaB response element. The FASEB Journal 17: 2334–2336

Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M & Cato AC (2001) Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20: 7108–7116